摘要
目的观察常规治疗和重组人脑利钠肽(rhBNP)对急性重症病毒性心肌炎伴充血性心力衰竭(ASVMC-CHF)的短期疗效。方法确诊ASVMC-CHF心功能Ⅱ～Ⅳ级的患者12例,随机分为常规治疗组和rhBNP组,rhBNP组在常规治疗基础上给予静脉注射rhBNP治疗。观察两组用药前后血压、心率、呼吸困难程度、肺毛细血管楔压、尿量、血清生化指标、心功能分级(NYHA)、相关血流动力学指标及相关心功能指标的变化。结果两组比较,用药后rhBNP组血压、心率、呼吸困难程度、肺毛细血管楔压较常规治疗组明显降低(P<0.05),血钾水平rhBNP组较常规治疗组明显提高(P<0.05),两组心功能分级都较治疗前降低,但差异无统计学意义(P>0.05)。两组尿量及心排指数(CI)较用药前明显增加,但组间差异无统计学意义(P>0.05)。本研究未发现与rhBNP有关的不良反应。结论 rhBNP能明显改善ASVMC-CHF患者血流动力学紊乱状态及临床症状,且安全性较高。
Objective To investigate the clinical efficacy of intravenous injection of recombinant human brain natriuretic peptide（rhBNP） in the treatment of patients of sever myocarditis complicated with heart failure.Methods Twelve patients were randomly divided into two groups：routine treatment group（n=6,treated by routine treatment） and rhBNP group（n=6,treated by rhBNP plus routine medicine）.PCWP and CI were taken at four time points：30 minutes before administration and 1 h,12 h,24 h after administration.Blood pressure,heart rate,dyspnea grade,24 hours fluid output and improvement in patient symptoms and signs were evaluated.The adverse reactions were documented.Results There were significant differences between the two groups in the decrease of heart rate,dyspnea grade,frequency of respiration,degree of pulmonary capillary wedge pressure,but no significant difference was found in cardiac index.The urine and CI were significantly increased after treatment,showing no statistically significant difference between the two groups.No rhBNP related adverse reactions were observed.Conclusion rhBNP is effective for treating patients of sever myocarditis complicated with heart failure.
出处
《海南医学》
CAS
2012年第13期23-25,共3页
Hainan Medical Journal
关键词
重组人脑利钠肽
重症心肌炎
心力衰竭
Recombinant human brain natriuretic peptide； Myocarditis； Heart failure
